Payment overview · 2025
General Payments
$210.33
11 reported records · 8 companies
Healthcare provider profile · identity verified
Maureen Zelinka, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT PIERCE, FL · NPI 1336119718
Verified facts
What the public records show
CMS Open Payments records show Maureen Zelinka, MD received $210.33 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.47 | 32.1% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.52 | 12.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.01 | 10.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.79 | 10.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.33 | 10.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.52 | 8.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.45 | 8.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.24 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.33 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.47 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.47 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 413 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 124 |
| Alprazolam | Alprazolam | 299 | 70 |
| Metformin Hcl | Metformin Hcl | 290 | 100 |
| Lisinopril | Lisinopril | 284 | 86 |
| Losartan Potassium | Losartan Potassium | 278 | 98 |
| Eliquis | Apixaban | 236 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 71 |
| Gabapentin | Gabapentin | 211 | 68 |
| Omeprazole | Omeprazole | 195 | 78 |
| Furosemide | Furosemide | 192 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 188 | 39 |
| Simvastatin | Simvastatin | 173 | 50 |
| Tramadol Hcl | Tramadol Hcl | 151 | 39 |
| Meloxicam | Meloxicam | 146 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 52 |
| Sertraline Hcl | Sertraline Hcl | 140 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 138 | 17 |
| Trazodone Hcl | Trazodone Hcl | 136 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 40 |
| Potassium Chloride | Potassium Chloride | 125 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 47 |
| Atenolol | Atenolol | 103 | 33 |
| Lorazepam | Lorazepam | 98 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 32 |
| Allopurinol | Allopurinol | 87 | 27 |
| Levetiracetam | Levetiracetam | 84 | 16 |
| Carvedilol | Carvedilol | 83 | 34 |
| Prednisone | Prednisone | 83 | 57 |
| Mirtazapine | Mirtazapine | 80 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 28 |
| Donepezil Hcl | Donepezil Hcl | 77 | 23 |
| Glipizide | Glipizide | 76 | 32 |
| Azithromycin | Azithromycin | 75 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | suppressed |
| Clonazepam | Clonazepam | 65 | 13 |
| Montelukast Sodium | Montelukast Sodium | 65 | 23 |
| Ezetimibe | Ezetimibe | 63 | 23 |
| Fenofibrate | Fenofibrate | 62 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 21 |
| Famotidine | Famotidine | 60 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 17 |
| Mupirocin | Mupirocin | 60 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 21 |
| Temazepam | Temazepam | 54 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 43 |
| Clonidine Hcl | Clonidine Hcl | 53 | 22 |
| Ibuprofen | Ibuprofen | 51 | 27 |
| Valacyclovir | Valacyclovir Hcl | 50 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 15 |
| Nifedipine Er | Nifedipine | 47 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 14 |
| Celecoxib | Celecoxib | 44 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 14 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Pregabalin | Pregabalin | 41 | 15 |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 14 |
| Cephalexin | Cephalexin | 36 | 29 |
| Glimepiride | Glimepiride | 36 | 14 |
| Estradiol | Estradiol | 34 | 12 |
| Ozempic | Semaglutide | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 14 |
| Anastrozole | Anastrozole | 32 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Baclofen | Baclofen | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Nystatin | Nystatin | 16 | 13 |
| Ramipril | Ramipril | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.33 · 11 records | PFIZER INC. | AUSTEDO XR, BREZTRI, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, Korlym, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error